Patents by Inventor Hans-Jörg Kirner

Hans-Jörg Kirner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7504532
    Abstract: Synthesis methods for the preparation of intermediates which are suitable for the preparation of statin derivatives, and especially to synthesis methods for the intermediate of formula (VI) wherein Ra? and Rc? are each independently of the other hydrogen or hydroxy-protecting group, or together are a bridging hydroxy-protecting group; and Rb is a carboxy-protecting group.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 17, 2009
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Reinhold Öhrlein, Gabriele Baisch, Hans Jörg Kirner, Stephan Burkhardt, Martin Studer, Frank Bienewald
  • Patent number: 7317123
    Abstract: The invention relates to novel synthesis methods for the preparation of the intermediates, which are suitable for the preparation of statin derivatives, especially to novel synthesis methods of the intermediate of formula VI wherein Ra? and Rc? are each independently of the other hydrogen or a hydroxy-protecting group or together are a bridging hydroxy-protecting group, and Rb is a carboxy-protecting group, which methods are carried out by conversion of the intermediate of formula XVI wherein Ra? and Rc? are each independently of the other hydrogen or a hydroxy-protecting group, R* and R** are each independently of the other hydrogen or an amide-protecting group, and Rb is a carboxy-protecting group; which methods proceed to further new intermediates and methods for their preparation
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: January 8, 2008
    Assignee: Teva Pharmaceutical Industries, Ltd
    Inventors: Reinhold Öhrlein, Gabriele Baisch, Hans Jörg Kirner, Stephan Burkhardt, Martin Studer, Frank Bienewald
  • Patent number: 6939992
    Abstract: A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: September 6, 2005
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Paul Adriaan Van Der Schaaf, Franz Schwarzenbach, Hans-Jörg Kirner, Martin Szelagiewicz, Claudia Marcolli, Andreas Burkhard
  • Patent number: 6872853
    Abstract: A cystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: March 29, 2005
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Paul Adriaan Van Der Schaaf, Franz Schwarzenbach, Hans-Jörg Kirner, Martin Szelagiewicz, Claudia Marcolli, Andreas Burkhard, Regine Peter
  • Patent number: 6806386
    Abstract: The present invention relates to a process for the preparation of compounds of formula (1), in which R1, R2 and R3 independently of one another are hydrogen, halogen , trifluoromethyl of or C1-C4alkoxy, wherein a compound of formula (2), in which R1, R2 and R3 are as defined in formula (1), is reacted with methlyamine in the presence of a non-alcoholic solvent and, if desired, in the presence of a sulfonic acid catalyst to give the compound of formula (2) and, if desired, is subject to purification by recrystallization.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: October 19, 2004
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Marc Thommen, Andreas Hafner, Frédëric Brunner, Hans-Jörg Kirner, Roman Kolly
  • Patent number: 6693218
    Abstract: Described is a process for the preparation of compounds of formula (1a) which comprises reacting an isomeric mixture consisting of from 75 to 95% of compound of formula (2a) and from 5 to 25% of a compound of formula (2b) with methylamine, in a suitable solvent, to form a sertraline-imine isomeric mixture consisting of from 75 to 95% of formula (1a) and from 5 to 25% of formula (1b)(A1), or reacting an isomeric mixture consisting of from 75 to 95% of a compound of formula (2a) and from 5 to 25% of a compound of formula (2b) with methylamine, in a suitable solvent, using suitable methods of isolation to form an enriched sertraline-imine isomeric mixture, consisting of >99% of a compound of formula (1a) and <1% of a compound of formula (1b)(A2); and then subjecting the sertraline-imine isomeric mixture obtained according to reaction route (A1) or (A2), in a suitable solvent, to recrystallisation (B), in accordance with scheme (I) wherein in formula (1a), R1, R2 and R3 are each independently of the others
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: February 17, 2004
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Marc Thommen, Andreas Hafner, Roman Kolly, Hans-Jörg Kirner, Frédéric Brunner